Tyra Biosciences reports positive Phase 2 SURF302 results
Tyra Biosciences said initial Phase 2 SURF302 results were favorable and selected 60 mg once-daily as the potential dose for its planned registrational adjuvant strategy.
Key Highlights:Original SEC Filing: Tyra Biosciences, Inc. [ TYRA ] - 8-K - Sep. 09, 2026This is an AI-powered summary. It may c…